Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions

To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Oncologic Diseases

Age range

1 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of Medicine

Asyut, Egypt

About this study

18-f FDG is used on oncological patients undergoing PET/CT study at our nuclear medicine unit , its uptake by the tissues depends on glucose blood level and consumption then we evaluate the implications of biological and procedural factors on the uptake by normal organs and neoplastic lesions using standardized uptake values SUVmax , mean and peak.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

cancer patients referred to nuclear medicine unit

Exclusion criteria

patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs

Treatment and study plan

18 FDG (Fludeoxyglucose 18F)

Radiation

18-f FDG

Primary outcomes

PET/CT scan on cancer patient will be performed to evaluate the biological and procedural factors of 18-f FDG uptake by multiple normal organs and neoplastic lesions using Standardized uptake values

Time frame: 2 years

SUV mean , suv peak and suv max

Study contacts

Contact information is provided by the study sponsor or research team.

Mahenoor Alaa Abouelouon, Master

CONTACT

[email protected]

201000488247

nadia mohany mostafa, assistant professor

CONTACT

[email protected]

01125006468

Sponsors and collaborators

Lead sponsor

mahenoor alaa eldeen naem

Other

Registry information

Official study title

Implications of Biological and Procedural Factors of 18-f FDG PET/CT Uptake by Normal Organs and Neoplastic Lesions

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Oct 4, 2024
Registry last updated: Oct 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting